SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported) – January 11, 2006
WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)
|
Pennsylvania |
|
1-8036 |
|
23-1210010 |
|
(State or other jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
|
of Incorporation) |
|
|
|
Identification No.) |
|
|
|
|
|
|
|
101 Gordon Drive, PO Box 645, Lionville, PA |
|
19341-0645 |
||
|
(Address of principal executive offices) |
|
(Zip Code) |
||
610-594-2900
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure
On January 11, 2006, West Pharmaceutical Services, Inc. (the “Company”) issued a press release updating its earnings for the fourth quarter and full year 2005 and reaffirming its 2006 sales target. The release also noted that Donald E. Morel, Jr., Ph.D., the Company’s Chairman and Chief Executive Officer, and William J. Federici, the Company’s Chief Financial Officer, will be presenting at the CJS Securities Investor Conference in New York, NY on January 12, 2006. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Attached hereto as Exhibit 99.2 and incorporated herein by reference, is the Corporate Overview (Investor Presentation) to be given by Dr. Morel and Mr. Federici at the conference.
The information in this report (including Exhibit 99.1 and 99.2) is being furnished pursuant to Item 7.01 Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
Item 9.01 Financial Statement and Exhibits
(c) Exhibits
|
Exhibit # |
|
Description |
|
|
|
|
|
99.1 |
|
West Pharmaceutical Services, Inc. Press Release, dated January 11, 2006. |
|
|
|
|
|
99.2 |
|
West Pharmaceutical Services, Inc. Corporate Overview (Investor Presentation). |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
WEST PHARMACEUTICAL SERVICES, INC. |
|
|
|
|
|
/s/ John R. Gailey III |
|
|
John R. Gailey III |
|
|
Vice President and General Counsel |
January 11, 2006
3
Exhibit Index
|
Exhibit |
|
|
|
|
|
|
|
99.1 |
|
West Pharmaceutical Services, Inc. Press Release, dated January 11, 2006. |
|
|
|
|
|
99.2 |
|
West Pharmaceutical Services, Inc. Corporate Overview (Investor Presentation). |
4